Latest news with #Breztri
Health Line
18 hours ago
- Health
- Health Line
The Cost Breztri of with Medicare
Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) is a metered-dose inhaler designed for adults living with chronic obstructive pulmonary disease (COPD). Medicare might help cover the cost of Breztri for COPD, but it's important to check the specifics of your plan, as there's no nationwide rule for inhaler coverage. Each Medicare Part D or Medicare Advantage Prescription Drug (MAPD) plan may cover different drugs. However, note that if you need a nebulizer rather than an inhaler, you would typically be covered under Medicare Part B. How much does Breztri cost with Medicare? If you don't have insurance, a 5.9-gram (g) Breztri inhaler costs around $400, while a larger 10.7-g inhaler can cost about $700. Whether your Medicare drug plan covers a Breztri inhaler depends on its formulary, which is a list of covered medications that varies with each plan. If your plan's formulary doesn't include this inhaler, it might offer coverage for a different one instead. If your plan covers Breztri, the amount you need to pay depends on its tier within the formulary. Higher tiers usually mean a higher cost. However, starting in 2025, you'll pay no more than $2,000 annually out of pocket for drugs through Medicare plans. Remember, Part D and MAPD plans are managed by private insurance companies, meaning your deductibles, premiums, and copays will depend on your plan. In 2025, the national base beneficiary premium for Part D is $36.78, and according to the Centers for Medicare & Medicaid Services (CMS), the average monthly premium for Medicare Advantage plans is about $17. If you use a nebulizer and have coverage under Part B, you'll pay 20% of the cost after meeting your annual deductible of $257, as long as you keep up with your monthly premium of $185. How can I get cheaper Breztri with Medicare? Typically, you can get cheaper drugs through your Medicare plan by getting a prescription for a generic version. These tend to feature in lower formulary tiers, making them more affordable. There's no generic version of Breztri, but other medications may be just as effective and more budget-friendly. Your Medicare plan may cover these. In fact, since Breztri can be expensive, your plan might require prior authorization before they approve coverage. This could involve step therapy, where you're asked to try a different, equally effective but cheaper medication first. In addition, AstraZeneca, the company that produces Breztri, offers a cost assistance program that may make this drug more affordable for Medicare enrollees. You'll need to visit the manufacturer's website to check your eligibility. Takeaway Breztri is a brand-name inhaler designed for long-term management of chronic obstructive pulmonary disease (COPD) in adults. Although Medicare drug plans may cover COPD inhalers like Breztri, coverage is not uniformly required. This means your coverage and cost depend on the specific medication and your specific plan. Generally, Medicare Part D or a Medicare Advantage Prescription Drug (MAPD) plan provides drug coverage for Medicare, including for covered inhalers. However, if you need to use the drug with a nebulizer, your coverage would fall under Part B.
Yahoo
09-05-2025
- Business
- Yahoo
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
This week Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca's AZN late-stage asthma study on inhaled triple-combination therapy, Breztri, met its key goals. Here's a recap of the week's most important stories. Novo Nordisk missed estimates for sales while earnings were in line. Revenues rose 18% at a constant exchange rate (CER), driven mainly by its GLP-1 products. Its GLP-1 sales increased 11% at CER. Total Diabetes care rose 8% and Obesity care sales increased 65% at CER. Sales of the diabetes drug Ozempic (semaglutide) rose 15%, while obesity injection Wegovy (semaglutide) rose 83% at CER. Rare disease segment sales rose 3%. Novo Nordisk also lowered its sales and operating profit outlook for the year due to lower-than-expected growth of its GLP-1 products due to competition from compounded versions of Wegovy. In 2025, Novo Nordisk expects sales to rise 13-21% at CER versus the prior expectation of 16-24%. Operating profit growth is expected to increase in the range of 16-24% at CER versus the prior expectation of 19-27%. Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings release. This is because Novo Nordisk said on the first-quarter call that it expects sales of Wegovy to improve going forward. The FDA has removed NVO's semaglutide medicines from its shortage list and has enforced those compounded versions be taken off the market by the end of the month. This should lead to a decline in compounded GLP-1 use, which can help Wegovy sales to rebound in the second half. Moreover, the company is also working to improve access for Wegovy such as through its direct-to-patient program, NovoCare Pharmacy as well its CVS deal. CVS has selected Wegovy as its preferred weight loss drug for its Caremark customers, excluding rival Lilly's obesity drug, Zepbound. Novo Nordisk also announced that it has filed regulatory applications seeking approval for the oral version of Wegovy (25mg) for the treatment of obesity. Novo Nordisk is the first company to seek approval for an oral GLP-1 drug for treating obesity. Jazz missed estimates for both earnings and sales. Total revenues of $897.8 million declined 0.5% year over year while earnings of $1.68 per share declined 36%. Sales of Jazz's neuroscience products rose 4% to $605.2 million while oncology product sales declined 11% to $229.4 million. In the neuroscience franchise, Xywav recorded sales of $344.8 million, up 9% year over year. Sales of Epidiolex/Epidyolex rose 10% to $217.7 million. In the oncology franchise, Rylaze/Enrylaze posted sales of $94.2 million, which fell 8% year over year, while Zepzelca recorded sales worth $63 million, down 16%. Vyxeos generated sales of $29.5 million, down 8%. While Jazz reiterated its total sales guidance, it cut its earnings outlook for 2025 to account for the acquisition of clinical-stage biotech, Chimerix, which closed last month. Total revenues are expected to be in the range of $4.15-$4.40 billion. Adjusted EPS guidance was lowered from a range of $22.50-$24.00 to $4.00-$5.60per share. AstraZeneca's two-phase III studies evaluating its inhaled triple-combination therapy, Breztri Aerosphere in patients with uncontrolled asthma met all primary endpoints. Breztri Aerosphere is a fixed dose combination of budesonide, glycopyrronium and formoterol fumarate. In the KALOS and LOGOS studies, Breztri led to a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. Data from these phase III studies will be shared with regulatory authorities. Breztri is presently approved to treat chronic obstructive pulmonary disease (COPD) in several countries including the United States and EU. The European Commission granted marketing authorization to AstraZeneca's BTK inhibitor, Calquence, as a combination treatment, for first-line mantle cell lymphoma (MCL), a rare and typically aggressive form of non-Hodgkin lymphoma. The approval was based on data from the ECHO phase III study. Calquence in combination with bendamustine and rituximab is already approved in the United States and several other countries for previously untreated MCL based on the ECHO data. Novo Nordisk and AstraZeneca have a Zacks Rank #2 (Buy) each, while Jazz carries a Zacks Rank of 3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The NYSE ARCA Pharmaceutical Index has declined 3.2% in the past five trading sessions. Large Cap Pharmaceuticals Industry 5YR % Return Here's how the eight major stocks performed in the previous five trading sessions. Image Source: Zacks Investment Research In the last five trading sessions, J&J rose the most (1.6%) while Merck declined the most (10.8%). In the past six months, AbbVie rose the most (8.4%) while Novo Nordisk declined the most (39.8%). (See the last pharma stock roundup here: J&J's Q1 Results, PFE's Obesity Setback) Watch this space for regular pipeline and regulatory updates next week. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Business
- Yahoo
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and Symbicort pressurized metered-dose inhaler (pMDI). KALOS and LOGOS included approximately 4,400 randomized trials met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. No new safety or tolerability signals were identified for Breztri in KALOS or LOGOS. Full results from the two Phase 3 trials will be shared with regulatory authorities and presented at an upcoming medical meeting. Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan. In addition to the two registrational trials (KALOS and LOGOS), two qualifying trials, LITHOS and VATHOS, also met their primary endpoints. LITHOS and VATHOS included approximately 1,000 randomized patients. In April, Sanofi SA (NASDAQ:SNY) reported preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in heterogeneous inflammatory asthma. The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses. Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60. A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident. In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60. AstraZeneca announced in its first-quarter presentation (PDF) on Tuesday that it had stopped working on a phase 1 Alzheimer's disease drug and two phase 2 programs for migraine and osteoarthritis pain and painful diabetic neuropathy. On Tuesday, the European pharma giant reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the consensus of $13.71 billion, driven by double-digit growth in oncology and biopharmaceuticals. Price Action: AZN stock is up 1.52% at $71.58 at the last check Friday. Read Next:Photo by Piotr Swat Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ASTRAZENECA (AZN): Free Stock Analysis Report This article AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
02-05-2025
- Business
- Yahoo
AstraZeneca's triple-combo triumphs in two Phase III asthma trials
AstraZeneca's triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma trials. Breztri met primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines, in the Phase III KALOS (NCT04609878) and LOGOS (NCT04609904) trials in patients with uncontrolled asthma. KALOS and LOGOS were randomised, double-blind trials that enrolled a total of 4,434 patients with asthma to investigate Breztri as a potential treatment. Director of the Respiratory Unit, CardioRespiratory Department, S. Anna University Hospital, Ferrara, Italy, Professor Alberto Papi said: 'Despite advancements in asthma treatments, millions of patients remain uncontrolled, which can cause frequent breathlessness, coughing and wheezing, significantly impacting their ability to perform daily activities. "The results from the KALOS and LOGOS trials are exciting and demonstrate the potential of Breztri to evolve the standard of care to more effectively treat asthma in a single inhaled triple therapy for patients who remain uncontrolled with dual maintenance therapy.' Breztri did not show any unexpected safety or tolerability concerns in either trial. Full data from the two studies will be shared with regulatory authorities and presented at an upcoming medical meeting. Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease. It received approval from the US Food and Drug Administration (FDA) on 24 July 2020 based on positive data from the Phase III ETHOS trial (NCT02465567), which showed a significant reduction in exacerbations compared with dual-combination therapies. GlobalData forecasts that sales of Breztri will reach $2.32bn in 2030, with estimates indicating the drug will reach blockbuster status in 2025. GlobalData is the parent company of Clinical Trials Arena. Elsewhere in asthma, GSK is hoping for approval of its depemokimab as an add-on treatment for asthma after two Phase III trials, SWIFT-1 and SWIFT-2, met their primary endpoints. The FDA has set a Prescription Drug User Fee Act date of 16 December 2025. "AstraZeneca's triple-combo triumphs in two Phase III asthma trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Reuters
02-05-2025
- Health
- Reuters
AstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trials
May 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma, showing clinically meaningful improvement in lung function. The Anglo-Swedish drugmaker's therapy, already approved for the treatment of Chronic Obstructive Pulmonary Disease or "smoker's lung", was being compared with a dual-combination maintenance treatment in the trials. here. The results come as AstraZeneca targets $80 billion in revenue by 2030, after first-quarter sales this week missed expectations on weaker oncology drug performance. Asthma is a common but chronic lung disease that makes breathing difficult due to inflammation and muscle tightening. It affected 262 million people and caused 455,000 deaths in 2019, according to the World Health Organization, opens new tab. "The results from the ... trials are exciting and demonstrate the potential of budesonide/glycopyrronium/formoterol to evolve the standard of care to more effectively treat asthma in a single inhaled triple therapy," said Alberto Papi, primary investigator of the studies, referring to the compounds in Breztri Aerosphere. AstraZeneca said on Friday it would share detailed results from the trials with authorities and seek to broaden approvals for Breztri, which brought in sales of $978 million last year and competes with GSK's Trelegy Ellipta.
